Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities
Net loss	$ (9,338,000)	$ 1,715,000
Adjustments required to reconcile net loss to net cash used in operating activities:
Change in fair value of warrant liability	(2,403,000)	(9,304,000)
Warrants and other allocable expenses	431,000	213,000
Gain on re-valuation of liquidated damages liability		(120,000)
Amortization of patents	23,000	23,000
Depreciation	245,000	217,000
Stock-based compensation	1,698,000	253,000
Changes in operating assets and liabilities:
Accounts receivable	101,000	60,000
Accounts payable, accrued expenses, deferred revenue and other	482,000	(11,000)
Accrued severance	(298,000)	(64,000)
Prepaid expenses and other current assets	(49,000)	(446,000)
Net cash used in operating activities	(9,108,000)	(7,464,000)
Investing activities:
Purchases of property and equipment	(266,000)	(160,000)
Net cash used in investing activities	(266,000)	(160,000)
Financing activities:
Proceeds from warrant exercises		396,000
Costs of Series B redeemable convertible preferred stock conversion to common stock	(173,000)
Dividend payments	(80,000)
Proceeds from issuance of common stock, net	4,224,000	12,384,000
Net cash provided by financing activities	3,971,000	12,780,000
Net (decrease) increase in cash and cash equivalents	(5,403,000)	5,156,000
Cash and cash equivalents, beginning of period	9,370,000	6,581,000
Cash and cash equivalents, end of period	3,967,000	11,737,000
Supplemental schedule of non-cash financing activities:
Accretion of Series B redeemable convertible preferred stock	1,858,000	9,329,000
Fair value of warrant liability upon issuance	$ 1,816,000	$ 4,210,000